On March 19, 2025, John Bode, a Director at Zevra Therapeutics Inc (ZVRA, Financial), purchased 10,000 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now owns a total of 40,000 shares of the company.
Zevra Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company aims to address unmet medical needs through its innovative pipeline.
The recent purchase by John Bode is part of a broader trend of insider activity within the company. Over the past year, there have been five insider buys and four insider sells. Notably, John Bode has acquired a total of 20,000 shares in the past year, with no recorded sales.
On the day of the recent purchase, shares of Zevra Therapeutics Inc were trading at $7.96, resulting in a market cap of $432.386 million. The stock's GF Value is estimated at $8.87, giving it a price-to-GF-Value ratio of 0.9. This suggests that the stock is modestly undervalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
